1394 participants
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-05
- Start Date:
- 2021-12-14
- Completion:
- 2027-01-31
Conditions
- Renal Cell Carcinoma (RCC)
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Urothelial Carcinoma (UC)
- Solid Tumor
- Hepatocellular Carcinoma (HCC)
- Non-small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Clear Cell Renal Cell Carcinoma (ccRCC)
- Non-Clear Cell Renal Cell Carcinoma (nccRCC)
- Drug-Drug Interaction (DDI)
Interventions
- DRUG
No Results Yet